Can Human Cytomegalovirus Infections Spark Alzheimer’s …
Jan 2, 2025 · Jacob Raber OHSU; Posted: 03 Jan 2025 In this original and timely study, Readhead et al. followed up on their earlier data showing that an AD-related CD83(+) microglia subtype associated with increased immunoglobulinG4 (IgG4) in the transverse colon (Wang et al., 2024).In the current study, CD83(+) microglia in the superior frontal gyrus were associated …
ALZFORUM | NETWORKING FOR A CURE
2 days ago · Julio Rojas on Proteomics Lays Groundwork for FTD Biomarkers 09 Feb 2025; Agustin Ibanez on Proteomics Lays Groundwork for FTD Biomarkers 09 Feb 2025; Charlotte Teunissen on Proteomics Lays Groundwork for FTD Biomarkers 09 Feb 2025; Franklin Tseng on Leqembi Maintenance Dosing Approved in the U.S. 07 Feb 2025; David Weisman on Leqembi …
Ceperognastat - ALZFORUM
Aug 15, 2024 · Overview. Name: Ceperognastat Synonyms: LY3372689 Chemical Name: N-[4-fluoro-5-[[2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Therapy Type: Small Molecule Target Type: Tau Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2) Company: Eli Lilly & Co. Background. This …
Fast Plaque Clearance with Little ARIA? So Teases ... - ALZFORUM
15 Mar 2024. A record 4,700 people from 70 countries attended the 18th International Conference on Alzheimer’s and Parkinson’s Diseases, held March 5 to 9 in Lisbon, Portugal.
Is It Time to Approve Drugs Based on Amyloid Removal?
Dec 5, 2024 · Suzanne Schindler Washington University; John Morris Washington University School of Medicine; Posted: 08 Dec 2024 Aisen et al. suggest the possibility of treating individuals with biomarker evidence of amyloid plaques with anti-amyloid treatments, regardless of whether these individuals have cognitive impairment, and they provide a strong scientific rationale for …
Posdinemab - ALZFORUM
Jun 28, 2024 · Overview. Name: Posdinemab Synonyms: JNJ-63733657 Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Mild AD U.S. FDA Status: Mild AD (Phase 2) Company: Janssen Background. This humanized IgG1 monoclonal antibody binds the proline-rich domain of tau, on the rationale that such antibodies will more potently interfere …
Cinpanemab - ALZFORUM
May 8, 2024 · Overview. Name: Cinpanemab Synonyms: BIIB054, NI-202 Therapy Type: Immunotherapy (passive) Target Type: alpha-synuclein Condition(s): Parkinson's Disease U.S. FDA Status: Parkinson's Disease (Discontinued) Company: Biogen, Neurimmune Background. Cinpanemab is a human-derived monoclonal antibody directed against α-synuclein. Genetic …
ACI-35 | ALZFORUM
Dec 15, 2023 · Overview. Name: ACI-35 Synonyms: VAC20121, JNJ-64042056 Therapy Type: Immunotherapy (active) Target Type: Tau Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2/3) Company: AC Immune SA, Janssen Background. ACI-35 is a liposome-based vaccine. The rationale behind it is that the vaccine will treat tauopathy in …
ALZ-801 | ALZFORUM
Sep 23, 2024 · Overview. Name: ALZ-801 Synonyms: valiltramiprosate, NRM-8499, homotaurine prodrug, 3-APS Therapy Type: Small Molecule Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 3) Company: Alzheon Inc. Background. This is a prodrug of homotaurine, a modified amino acid previously developed …
What Happens After Amyloid Plaque Removal? Who Benefits Most?
14 Apr 2023. Even though there were no big revelations from immunotherapy trials at this year’s International Conference on Alzheimer’s and Parkinson’s Diseases, held March 28 to April 1 in Gothenburg, Sweden, new data from several programs deepened the field’s understanding of what happens when amyloid plaque is cleared from a person's brain.